
    
      Prospective, open label, single blind, randomized study with inclusion of 160 patients in two
      equal sized cohorts (A and B). Angiographic follow-up with optical coherence tomography (OCT)
      is performed at 1 month (Cohort A) and 3 months (Cohort B). Randomization 1:1 to SYNERGY or
      BioMatrix Neoflex. The Cohorts are included consecutively, Cohort A first.
    
  